Latent Tuberculosis Infection: A Primary Care Perspective

Duncan Reid, MD International Medicine Clinic Harborview Medical Center 12 July 2023

Quick Poll

Where do you work?

What do you do?

What risk factors for TB do your patients have?


Challenges to screening, treatment?

My Background

- Primary Care Physician
- International clinic: patients mostly from Vietnam, Cambodia, Ethiopia, Eritrea, and Somalia
 - all with incidence of 40 cases per 100,000 persons or greater
- Majority of established patients have been tested at some point, not all have been treated
- Recent immigrants mostly not yet tested for LTBI

Learning Objectives

- Explain what latent tuberculosis infection means in simple terms
- Counsel patient on reactivation risks and treatment options
- Address common patient concerns which might affect completing course of treatment



Targeted screening: a moving target

Higher risk for recent infection

- Close contacts with those who have TB disease
- Immigrant from country where TB disease is common (>1 month residence)
- People who live or work in high-risk settings

Higher risk for progression

- HIV infected
- Abnormal CXR consistent with TB, untreated
- Health care providers
- Infants/children < 5 years of age
- Specific medical conditions

Low	Intermediate (RR 1.3 – 2.8)	High (RR 2.8 – 10)
No risk Factors	Chronic renal failure 2.4 (2.1 – 2.8); Pablos-Mendez et al	HIV infection, advanced and untreated 9.9 (8.7 – 11); Moss et al
	Treatment with TNF- alpha inhibitor 2.0 (1.1-3.5); Jick et al	Close contact with a person wit active TB infection 6.1 (5.5-6.8); Ferebee
	Poorly controlled diabetes 1.7 (1.5 – 2.2); Pablos-Mendez et al	CXR with evidence of prior TB (untreated) 5.2 (3.4 – 8.0); Ferebee
	Smoking 1.5 (1.1 – 2.2); Bates et al	Treatment with >15mg prednisone for > 1 month 2.8 (1.7-4.6); Jick et al

Low	Intermediate (RR 1.3 – 2.8)	High (RR 2.8 – 10)
No risk Factors	Chronic renal failure 2.4 (2.1 – 2.8); Pablos-Mendez et al	HIV infection, advanced and untreated 9.9 (8.7 – 11); Moss et al
	Treatment with TNF- alpha inhibitor 2.0 (1.1-3.5); Jick et al Poorly controlled diabetes 1.7 (1.5 – 2.2); Pablos-Mendez et al Smoking 1.5 (1.1 – 2.2); Bates et al	Close contact with a person with active TB infection 6.1 (5.5-6.8); Ferebee
		CXR with evidence of prior TB (untreated) 5.2 (3.4 – 8.0); Ferebee
		Treatment with >15mg prednisone for > 1 month 2.8 (1.7-4.6); Jick et al

Targeted screening

- What proportion of patients who you care for are tested for TB infection?
- Are there any particular groups which are missed in your practice?

Considerations for treatment

- What other medical priorities does the patient have?
- Likelihood of progression versus risks of treatment
 - Can use tool such as TSTin3D to estimate lifetime risk
 - Baseline risk of progression between 5% to 15% lifetime risk
- Assess the likelihood of completion
 - Patient motivation
 - Resources for adherence, ability to pick up refills, close follow-up
 - Education

How do you explain latent TB infections to patients?

- What do you know about tuberculosis infection?
 - Personal/family experience
- Sleeping vs awake analogy
- Normalizing latent TB infection
 - Over 20 percent of the global population has been infected with latent TB
- What concerns do you have about treatment?
 - Treatment for active disease vs latent infections

Common concerns about latent TB infection

- 1. Can Linfect others?
- 2. Will I be able to work?
- 3. Will my community shun me?
- 4. Why should I undergo treatment now if I feel fine?
- 5. Side effects of treatment?
- 6. Will I need to be tested for TB again following treatment?
- 7. Can I develop TB despite having received the BCG vaccine?

Common concerns about latent TB infection

Any other concerns that your patients bring up?

Treatment options

POLL: What is the most common treatment regimen that you prescribe?

- Rifampin daily for 4 months
- Isoniazid (INH) and rifapentine weekly for 3 months
- Isoniazid and Rifampin daily for 3 months
- Isoniazid (INH) daily for 9 months

Selecting a course

- Use patient identified priorities to select treatment regimen: duration, side effects, pill burden
- Shorter courses more likely to be completed
- Common side effects: risk of hepatitis with INH, GI symptoms with rifampin
- Comorbidities: underlying liver disease, neuropathy, medications
- Medication interactions with rifampin and rifapentine

What else can I do to support adherence

- DOT can increase completion rates, but this can also create a barrier based on frequency of visits
- Increased frequency of follow-up during treatment can help ensure course completion
- Incentives do not have clear benefit according to some studies
- Anything that your clinic does that has been helpful?

Special situations

- What is the upper age limit that you would treat a latent TB infection?
- Undocumented/unclear treatment history in the past? When to address LTBI?
- Symptoms / CXR with possible TB disease
- Concern for re-exposure, lengthy visits to highprevalence TB region

Case

- 65-year-old Vietnamese woman, emigrated at 40 years old
- Annual risk of development of active TB 0.1%
- Cumulative risk of active TB to age 80: 1.5%
- If treated with INH, likelihood of clinically significant hepatitis: 5%

Case

- Developed autoimmune hepatitis and required INH treatment prior to transplant.
- Revised active TB risk following transplant:
 - Annual risk 4.6%
 - Cumulative risk to age 80: 69%

EthnoMed Cultural Resource





- Resource for providers treating immigrant patients
- Based at Harborview Medical Center
- Tuberculosis information series
- TB Cultural Profiles (Google: Ethnomed TB Profile)
 - Somalian
 - Ethiopian
 - Vietnamese
 - Cambodian
 - Oromo

EthnoMed Cultural Resource

- New partnership with Public Health Seattle & King County (PHSKC) TB Program to develop additional TB resources in partnership with immigrant communities
- Planning a number of profiles in the coming months including:
 - Marshallese
 - Iraqi
 - Afghan
 - Ukranian



Learning Objectives

- Explain what latent tuberculosis infection means in simple terms
- Counsel patient on reactivation risks and treatment options
- Address common patient concerns which might affect completing course of treatment

CONTACT:

REIDD@UW.EDU

Duncan Reid

References

- Bates MN, Khalakdina A, Pai M, Chang L, Lessa F, Smith KR. Risk of tuberculosis from exposure to tobacco smoke: a systematic review and meta-analysis.
- Ferebee SH. Bibl Tuberc 1970;26:28-106.
- Grimes CZ, Hwang LY, Williams ML, Austin CM, Graviss EA. Int J Tuberc Lung Dis 2007;11:1183-9.
- Jick SS, Lieberman ES, Rahman MU, Choi HK. Arthritis Rheum 2006;55:19-26.
- Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Am JRespir Crit Care Med 2000;162:460-4.
- Pablos-Méndez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997;87:574-9.